Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

839 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy and tolerability of tirbanibulin 1% ointment in the treatment of cancerization field: a real-life Italian multicenter observational study of 250 patients.
Nazzaro G, Carugno A, Bortoluzzi P, Buffon S, Astrua C, Zappia E, Trovato E, Caccavale S, Pellegrino V, Paolino G, Balestri R, Lacava R, Ciccarese G, Verdelli A, Barruscotti S, Valenti M, Toni G, Giacalone S, Zavattaro E, Gironi LC, Mercuri SR, Ribero S, Gisondi P, Sena P, Marzano AV. Nazzaro G, et al. Among authors: valenti m. Int J Dermatol. 2024 Nov;63(11):1566-1574. doi: 10.1111/ijd.17168. Epub 2024 Apr 11. Int J Dermatol. 2024. PMID: 38605473 Free article.
Real-Life Effectiveness and Safety of Risankizumab in 131 Patients Affected by Moderate-to-Severe Plaque Psoriasis: A 52-Week Retrospective Study.
Gargiulo L, Ibba L, Pavia G, Vignoli CA, Piscazzi F, Valenti M, Sanna F, Perugini C, Avagliano J, Costanzo A, Narcisi A. Gargiulo L, et al. Among authors: valenti m. Dermatol Ther (Heidelb). 2022 Oct;12(10):2309-2324. doi: 10.1007/s13555-022-00795-x. Epub 2022 Sep 5. Dermatol Ther (Heidelb). 2022. PMID: 36063283 Free PMC article.
Real-life effectiveness of tildrakizumab in chronic plaque psoriasis: A 52-week multicentre retrospective study-IL PSO (Italian landscape psoriasis).
Narcisi A, Valenti M, Gargiulo L, Ibba L, Amoruso F, Argenziano G, Bardazzi F, Burlando M, Carrera CG, Damiani G, Dapavo P, Dini V, Franchi C, Girolomoni G, Guarneri C, Loconsole F, Sampogna F, Travaglini M, Malagoli P, Costanzo A. Narcisi A, et al. Among authors: valenti m. J Eur Acad Dermatol Venereol. 2023 Jan;37(1):93-103. doi: 10.1111/jdv.18594. Epub 2022 Oct 5. J Eur Acad Dermatol Venereol. 2023. PMID: 36156312 Free PMC article.
A risankizumab super responder profile identified by long-term real-life observation-IL PSO (ITALIAN LANDSCAPE PSORIASIS).
Gargiulo L, Ibba L, Malagoli P, Amoruso F, Argenziano G, Balato A, Bardazzi F, Burlando M, Carrera CG, Damiani G, Dapavo P, Dini V, Fabbrocini G, Franchi C, Gaiani FM, Girolomoni G, Guarneri C, Lasagni C, Loconsole F, Marzano AV, Maurelli M, Megna M, Orsini D, Sampogna F, Travaglini M, Valenti M, Costanzo A, Narcisi A. Gargiulo L, et al. Among authors: valenti m. J Eur Acad Dermatol Venereol. 2024 Jan;38(1):e113-e116. doi: 10.1111/jdv.19464. Epub 2023 Aug 29. J Eur Acad Dermatol Venereol. 2024. PMID: 37611277 No abstract available.
839 results